---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011509"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:18:08.142363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study

## Summary
- Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.
- Poster: 'Endocrinologists’ Perspectives on an Implantable CBGM' on Aug 9, 12:00-1:00 PM MST.
- Preparing to begin long-term early feasibility study after successful initial clinical validation.
- CBGM is fully implantable, lasts up to 3 years, measures blood glucose directly with no on-body wearable.

## SEC filing metadata
- accession: 0001493152-25-011509
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011509/0001493152-25-011509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011509/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011509
- JSON: https://secwatch.observer/filing/0001493152-25-011509.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.